Comments highlight difficulties in understanding statistical analysis linking bupropion/naltrexone and weight loss in a retrospective cohort.
Naude et al. [ 1 ] evaluated whether there were additive effects of prescribing bupropion/naltrexone on top of a glucagon-like peptide 1 (GLP-1) analogue as weight loss therapy. GLP-1 analogues are known to be an effective treatment for weight loss, and the authors stated based on their analysis that the addition of bupropion/naltrexone was associated with greater weight loss, including in patients who were initially non-responsive to GLP-1 analogues. On our initial review of the article, we found the description and results of the analysis to be hard to follow. Specifically, our concerns focus on the following:
No takes yet. Share an insight, caveat, or question.
Mokalla et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: